HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BMI 1026

structure in first source

Also Known As:

BMI-1026; BMI1026

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Phenols: 677
        BMI 1026: 1
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - BMI 1026: 1

Experts

1.	Kang, Hyunsu: 1 article (04/2021)
2.	Kim, Dong Eun: 1 article (04/2021)
3.	Kim, Ki-Suk: 1 article (04/2021)
4.	Kim, Shin: 1 article (04/2021)
5.	Kwon, Taeg Kyu: 1 article (04/2021)
6.	Lee, Jinho: 1 article (04/2021)
7.	Nam, Yu Ri: 1 article (04/2021)
8.	Park, Jong Wook: 1 article (04/2021)

Related Diseases

1.	Renal Cell Carcinoma (Grawitz Tumor) 04/20/2021 - "This study was conducted to investigate the anticancer mechanisms of BMI-1026 on human renal carcinoma Caki cells. " 04/20/2021 - "Cyclin-Dependent Kinase Inhibitor BMI-1026 Induces Apoptosis by Downregulating Mcl-1 (L) and c-FLIP (L) and Inactivating p-Akt in Human Renal Carcinoma Cells."
2.	Cardiotoxicity 04/20/2021 - "Electrophysiological safety was confirmed by determining the cardiotoxicity of BMI-1026 via left ventricular pressure analysis. "
3.	Neoplasms (Cancer) 04/20/2021 - "However, the molecular mechanisms by which BMI-1026 treatment leads to cancer cell death remain unclear. "

Related Drugs and Biologics

1.	CASP8 and FADD-Like Apoptosis Regulating Protein (FLIP-S)
2.	Cyclin-Dependent Kinases (cdk Proteins)